Originally published as JCO Early Release 10.1200/JCO.2005.55.405 on August 8 2005

This Article Full Text Full Text (PDF) Publisher's Note Erratum (v24,p1966) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Belani, C. P. Articles by Curran, W. J. Search for Related Content PubMed PubMed Citation Articles by Belani, C. P. Articles by Curran, W. J., Jr Related Articles Related Editorial Social Bookmarking                            What's this?

Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol

From the University of Pittsburgh Cancer Institute, Pittsburgh, PA; The University of Texas Southwestern Medical Center, Dallas, TX; Rush Medical College, Rush University Medical Center, Chicago, IL; American College of Radiology, Reston, VA; Highlands Oncology Center, Fayetteville, AR; Dayton Community Clinical Oncology Program, Dayton, OH; Thomas Jefferson University, Philadelphia, PA

Address reprint requests to Chandra P. Belani, MD, Professor of Medicine, University of Pittsburgh School of Medicine, Co-Director, Lung and Thoracic Malignancies Program, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Ave, 5th Floor, Pittsburgh, PA 15232; e-mail: belanicp{at}upmc.edu

PURPOSE: This phase II noncomparative randomized trial was conducted to determine the optimal sequencing and integration of paclitaxel/carboplatin with standard daily thoracic radiation therapy (TRT), in patients with locally advanced unresected stage III non–small-cell lung cancer (NSCLC). Survival data were compared with historical standard sequential chemoradiotherapy data from the Radiation Therapy Oncology Group.

PATIENTS AND METHODS: Patients with unresected stages IIIA and IIIB NSCLC, with Karnofsky performance status 70% and weight loss 10%, received two cycles of induction paclitaxel (200 mg/m²)/carboplatin (area under the plasma concentration time curve [AUC] = 6) followed by TRT 63.0 Gy (arm 1, sequential) or two cycles of induction paclitaxel (200 mg/m²)/carboplatin (AUC = 6) followed by weekly paclitaxel (45 mg/m²)/carboplatin (AUC = 2) with concurrent TRT 63.0 Gy (arm 2, induction/concurrent), or weekly paclitaxel (45 mg/m²)/carboplatin (AUC = 2)/TRT (63.0 Gy) followed by two cycles of paclitaxel (200 mg/m²)/carboplatin (AUC = 6; arm 3, concurrent/consolidation).

RESULTS: With a median follow-up time of 39.6 months, median overall survival was 13.0, 12.7, and 16.3 months for arms 1, 2, and 3, respectively. During induction chemotherapy, grade 3/4 granulocytopenia occurred in 32% and 38% of patients on study arms 1 and 2, respectively. The most common locoregional grade 3/4 toxicity during and after TRT was esophagitis, which was more pronounced with the administration of concurrent chemoradiotherapy on study arms 2 and 3 (19% and 28%, respectively).

CONCLUSION: Concurrent weekly paclitaxel, carboplatin, and TRT followed by consolidation seems to be associated with the best outcome, although this schedule was associated with greater toxicity.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

Supported by a grant from Bristol-Myers Squibb Company.

Presented in part at the 10th World Conference on Lung Cancer, Vancouver, British Columbia, Canada, August 10-14, 2003; the American Society of Clinical Oncology Annual Meetings on May 12-15, 2001 (37th; San Francisco, CA), May 18-21, 2002 (38th; Orlando, FL), and May 31-June 3, 2003 (39th; Chicago, IL); and the 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology, San Francisco, CA, November 4-8, 2001.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Optimal Therapy for Unresectable Stage III Non–Small-Cell Lung Cancer
  Everett E. Vokes
  JCO 2005 23: 5853-5855 [Full Text]

This article has been cited by other articles:

				V. Steger, T. Walles, B. Kosan, T. Walker, T. Kyriss, S. Veit, J. Dippon, and G. Friedel Trimodal Therapy for Histologically Proven N2/3 Non-Small Cell Lung Cancer: Mid-Term Results and Indicators for Survival. Ann. Thorac. Surg., June 1, 2009; 87(6): 1676 - 1683. [Abstract] [Full Text] [PDF]

				N. Hanna, M. Neubauer, C. Yiannoutsos, R. McGarry, J. Arseneau, R. Ansari, C. Reynolds, R. Govindan, A. Melnyk, W. Fisher, et al. Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology J. Clin. Oncol., December 10, 2008; 26(35): 5755 - 5760. [Abstract] [Full Text] [PDF]

				M. A. Socinski, A. W. Blackstock, J. A. Bogart, X. Wang, M. Munley, J. Rosenman, L. Gu, G. A. Masters, P. Ungaro, A. Sleeper, et al. Randomized Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemotherapy and Dose-Escalated Thoracic Conformal Radiotherapy (74 Gy) in Stage III Non-Small-Cell Lung Cancer: CALGB 30105 J. Clin. Oncol., May 20, 2008; 26(15): 2457 - 2463. [Abstract] [Full Text] [PDF]

				A. W. Blackstock and R. Govindan Definitive Chemoradiation for the Treatment of Locally Advanced Non Small-Cell Lung Cancer J. Clin. Oncol., September 10, 2007; 25(26): 4146 - 4152. [Abstract] [Full Text] [PDF]

				J. R. Jett, S. E. Schild, R. L. Keith, and K. A. Kesler Treatment of Non-small Cell Lung Cancer, Stage IIIB: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 266S - 276S. [Abstract] [Full Text] [PDF]

				E. E. Vokes, J. E. Herndon II, M. J. Kelley, M. G. Cicchetti, N. Ramnath, H. Neill, J. N. Atkins, D. M. Watson, W. Akerley, and M. R. Green Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B J. Clin. Oncol., May 1, 2007; 25(13): 1698 - 1704. [Abstract] [Full Text] [PDF]

				N. Wiedenmann, D. Valdecanas, N. Hunter, S. Hyde, T. A. Buchholz, L. Milas, and K. A. Mason 130-nm Albumin-Bound Paclitaxel Enhances Tumor Radiocurability and Therapeutic Gain Clin. Cancer Res., March 15, 2007; 13(6): 1868 - 1874. [Abstract] [Full Text] [PDF]

				J. Kurai, H. Chikumi, K. Hashimoto, K. Yamaguchi, A. Yamasaki, T. Sako, H. Touge, H. Makino, M. Takata, M. Miyata, et al. Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines Clin. Cancer Res., March 1, 2007; 13(5): 1552 - 1561. [Abstract] [Full Text] [PDF]

				F Mornex and N Girard Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art Ann. Onc., December 1, 2006; 17(12): 1743 - 1747. [Abstract] [Full Text] [PDF]

				R. M. Huber, M. Flentje, M. Schmidt, B. Pollinger, H. Gosse, J. Willner, and K. Ulm Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non-Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group J. Clin. Oncol., September 20, 2006; 24(27): 4397 - 4404. [Abstract] [Full Text] [PDF]

				T. E. Stinchcombe, D. Fried, D. E. Morris, and M. A. Socinski Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer Oncologist, July 1, 2006; 11(7): 809 - 823. [Abstract] [Full Text] [PDF]

				E. E. Vokes Optimal Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 2005; 23(25): 5853 - 5855. [Full Text] [PDF]